Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Terminated · Phase 1 · NCT05494762
Conditions: Solid Tumor
At a glance
- Research payments reported, 2025
- $27,185
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 55
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-B167 (drug), Tislelizumab (drug)
- Dates
- Started 2022-08-25; completion 2025-02-24
- Results posted
- Not yet
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.
From ClinicalTrials.gov, last updated 2025-05-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beigene, Ltd. reported $27,185 in research payments for this study in 2025 (6 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Marwan G. Fakih, MD Medical Oncology · Duarte, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $16,618
- City of Hope National Medical Ctr $10,567
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.